Incyte Corporation - Asset Resilience Ratio
Incyte Corporation (INCY) has an Asset Resilience Ratio of 6.94% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Incyte Corporation for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how Incyte Corporation's Asset Resilience Ratio has changed over time. See INCY net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Incyte Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Incyte Corporation (INCY) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $482.79 Million | 6.94% |
| Total Liquid Assets | $482.79 Million | 6.94% |
Asset Resilience Insights
- Limited Liquidity: Incyte Corporation maintains only 6.94% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Incyte Corporation Industry Peers by Asset Resilience Ratio
Compare Incyte Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Incyte Corporation (1999–2025)
The table below shows the annual Asset Resilience Ratio data for Incyte Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.94% | $482.79 Million | $6.96 Billion | -1.70pp |
| 2024-12-31 | 8.64% | $470.26 Million | $5.44 Billion | +2.11pp |
| 2023-12-31 | 6.53% | $442.67 Million | $6.78 Billion | +1.60pp |
| 2022-12-31 | 4.92% | $287.54 Million | $5.84 Billion | -0.97pp |
| 2021-12-31 | 5.89% | $290.75 Million | $4.93 Billion | -2.20pp |
| 2020-12-31 | 8.10% | $288.37 Million | $3.56 Billion | -0.21pp |
| 2019-12-31 | 8.31% | $284.87 Million | $3.43 Billion | -2.06pp |
| 2018-12-31 | 10.37% | $274.34 Million | $2.65 Billion | -1.36pp |
| 2017-12-31 | 11.73% | $270.14 Million | $2.30 Billion | +2.20pp |
| 2016-12-31 | 9.53% | $156.20 Million | $1.64 Billion | -8.96pp |
| 2015-12-31 | 18.50% | $186.34 Million | $1.01 Billion | +0.67pp |
| 2014-12-31 | 17.83% | $147.97 Million | $830.07 Million | +11.86pp |
| 2013-12-31 | 5.97% | $37.58 Million | $629.57 Million | +4.65pp |
| 2012-12-31 | 1.32% | $4.36 Million | $330.42 Million | -0.03pp |
| 2011-12-31 | 1.35% | $4.43 Million | $328.96 Million | +0.07pp |
| 2010-12-31 | 1.28% | $6.26 Million | $489.58 Million | -1.61pp |
| 2009-12-31 | 2.89% | $20.59 Million | $712.39 Million | -5.40pp |
| 2008-12-31 | 8.29% | $19.26 Million | $232.39 Million | -45.24pp |
| 2007-12-31 | 53.53% | $147.58 Million | $275.69 Million | -31.23pp |
| 2006-12-31 | 84.76% | $299.71 Million | $353.60 Million | -4.38pp |
| 2005-12-31 | 89.14% | $333.48 Million | $374.11 Million | +23.83pp |
| 2004-12-31 | 65.31% | $337.58 Million | $516.92 Million | -4.28pp |
| 2003-12-31 | 69.59% | $264.11 Million | $379.55 Million | -3.96pp |
| 2002-12-31 | 73.55% | $406.09 Million | $552.14 Million | +7.71pp |
| 2001-12-31 | 65.84% | $464.54 Million | $705.56 Million | +12.61pp |
| 2000-12-31 | 53.23% | $472.02 Million | $886.82 Million | +37.59pp |
| 1999-12-31 | 15.64% | $34.70 Million | $221.90 Million | -- |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more